To fully understand autoimmune diseases like multiple sclerosis (MS), it is necessary to study not just the immune system, but also the tissue that the immune system is attacking, a study suggests. “We must move away from the present ‘immune-centric-only’ view of autoimmune diseases,” Decio Eizirik, MD, PhD, study…
News
CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. Clinicians caring…
Desi Harrison, a multiple sclerosis (MS) patient and president of the nonprofit MS Warriors for a Cause, has donated $700,000 to support the Ochsner Neuroscience Institute. The funds will help support research and care at the Ochsner Multiple Sclerosis Center to ensure that patients — like Harrison, who…
Obesity and a higher body mass index (BMI) are associated with both increased multiple sclerosis (MS) risk and harmful autoimmune activity that is induced by leptin, a hormone secreted by fat cells, a study finds. These results indicate that leptin, which helps regulate…
Reduced exposure to sunlight, previously reported as a risk factor for developing multiple sclerosis (MS), also seems to increase the risk for relapse and worsening disability, data from two clinical studies suggest. The beneficial effects of sunlight exposure were linked to increased levels of vitamin D, but also modulation…
The Multiple Sclerosis Association of America (MSAA) is hosting a webinar in which experts will discuss the COVID-19 pandemic and its impact on multiple sclerosis (MS). The webinar, “What You Need to Know About COVID-19 and MS: Program 8,” will take place at 8 p.m.
The 2020 Sobek Research Prize has been given to Alan J. Thompson, MD, a physician scientist with University College London, for his pioneering work in progressive multiple sclerosis (MS), the National MS Society announced. The prize is jointly awarded by the German National MS Society (DMSG) and…
Levels of myelin sheath components called ceramides are altered in the blood of people with multiple sclerosis (MS) and may be linked with retinal degeneration and physical disability, a study has found. Specific ceramides were altered only in those with progressive…
People with multiple sclerosis (MS) tend to mentally overestimate the time required to complete a short walking activity, causing cognitive fatigue that may affect their quality of life, a study reports. The connection between cognitive fatigue and imagined motor exercises may offer a potential…
New research in mice suggests that poor recycling of cholesterol in the brain impairs the repair of myelin, the protective coat surrounding nerve cells that is lost in multiple sclerosis (MS). Pharmacological stimulation of cholesterol synthesis by brain immune cells — called microglia — boosted the regeneration of myelin,…
Children of diabetic mothers may be at more risk of developing multiple sclerosis (MS), a Danish national study suggests. The study, “Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study,” was published in the Multiple Sclerosis Journal. Previous studies have suggested a…
Multiple Sclerosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to multiple sclerosis (MS) throughout 2020, a year marked by the COVID-19 pandemic. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during…
The European Commission (EC) has approved a new, intramuscular formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing-remitting multiple sclerosis (RRMS). This new mode of administration — in which Plegridy is directly injected into the muscle, rather than under the skin (subcutaneously) — does…
People with multiple sclerosis (MS) are encouraged to complete a survey aimed at understanding the experiences and expectations of those with a chronic illness who have either participated in a clinical trial or may in the future. The questionnaire was created by Kayentis, an electronic solutions company, in…
Patient dosing has finished in a Phase 2 clinical trial testing NurOwn, BrainStorm Cell Therapeutics’ investigational cell-based therapy for people with progressive multiple sclerosis (MS), the company announced. The trial’s top-line results are…
Kesimpta (ofatumumab), the first self-administered B-cell therapy to treat relapsing forms of multiple sclerosis (MS), is now available via AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies operating in the U.S., to patients living in the country. The specialty pharmacy — which focuses on serving…
The prevalence of primary headaches — those with no clear cause — is high among patients with multiple sclerosis (MS), a new study suggests. Clinical screening of headache among MS patients could help tailor individualized treatments and ease the impact of the disease for these patients. The study, “…
Mayzent (siponimod) significantly improved cognitive processing speed in people with secondary progressive multiple sclerosis (SPMS) compared with a placebo, according to additional analyses of two-year data from the EXPAND Phase 3 trial. While…
The levels of a protein called Neuregulin-1 beta 1 (Nrg-1beta1) decline with the onset and progression of multiple sclerosis (MS), a new study suggests. The findings support the potential of Nrg-1beta1 as a predictor of MS risk and progression and suggest that restoring its levels may help halt disease…
Investigators are looking for people with progressive forms of multiple sclerosis (MS) to participate in two Phase 3 clinical trials assessing the safety and effectiveness of tolebrutinib (SAR442168), an oral BTK inhibitor that is being investigated as a potential treatment, the National Multiple Sclerosis Society announced…
Adults with mild to moderate multiple sclerosis (MS) are being urged to participate in a new clinical trial — STEP for MS — that will assess the impact of two different exercise programs on patients’ mobility, walking abilities, and quality of life. Funded by the Patient-Centered Outcomes Research…
Lesser or stable disability over two years was evident in most progressive multiple sclerosis (MS) patients given a stem cell treatment in a small Phase 1 clinical trial, supporting a larger study now underway, researchers report. These results suggest that a treatment using mesenchymal stem…
A new research project will seek to better understand the biological processes that drive memory problems in people with multiple sclerosis (MS), as a better understanding of these processes may open new avenues for intervention. The four-year study is titled “Neuroimaging of Hippocampally Mediated Memory Dysfunction in…
The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion…
Two global Phase 3 clinical trials, both comparing Sanofi Genzyme’s investigational tolebrutinib with its approved therapy Aubagio, are enrolling a total of 1,800 people with relapsing multiple sclerosis (MS), the company said. All patients in both studies — dubbed GEMINI 1 and GEMINI 2 — will…
Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active, relapsing forms of multiple sclerosis (MS), according to top-line data from the Phase 3 ULTIMATE trials. Full results, including data on safety and secondary goals, are expected to be presented…
Adults with multiple sclerosis (MS) are being urged to enroll in a new clinical trial — now recruiting in Washington and Michigan states — that aims to assess the effectiveness of different treatments to counteract the effects of chronic fatigue. The investigators are hopeful that data from this…
The pro-inflammatory environment characteristic of multiple sclerosis (MS) reduces the levels of PPAR-gamma — a receptor protein whose activation dampens inflammation — and impairs myelin processing in immune cells that clear myelin debris, a study suggests. These findings may help to better understand how PPAR-gamma regulates the function of these…
Despite having more severe first and second relapses, children with relapsing-remitting multiple sclerosis (RRMS) tend to recover better than adults with the disease, according to a study. Better recovery in children may be linked to the activation of genes that, in turn, impair the activation of immune cells driving…
Autologous hematopoietic stem cell transplant (AHSCT) induces a reduction in relapse rate and physical disability in patients with relapsing-remitting multiple sclerosis (RRMS) who respond inadequately to other treatments, a small study suggests. The study, “Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation…